Biogen Advances Pipeline and Expands into Immunology and Nephrology
Biogen is entering a pivotal phase with its pipeline as it prepares for clinical readouts from ten Phase III programs starting in the fourth quarter. The company aims to offset declining revenues from its legacy multiple sclerosis (MS) business by diversifying beyond neurology, focusing on immunology and nephrology. This includes developing felzartamab for antibody-mediated kidney transplant rejection and exploring additional indications. Biogen's acquisition of Apellis has added commercial products like SYFOVRE and infrastructure to support future launches. The company expects $250 million in annualized cost savings by the end of next year, while managing interest costs from the acquisition debt it plans to pay down by 2027. Management also intends to pursue earlier-stage deals across immunology, rare diseases, and neurology through 2027. Biogen's CFO emphasized progress in launching growth products that offset erosion in its MS portfolio and reshape its research pipeline. The company is optimizing costs under the Fit for Growth initiative while redirecting investment toward newer launches such as LEQEMBI, SKYCLARYS, and ZURZUVAE.
Tickers: $BIIB
Topics: acquisitions biotech clinical trials diversification